Breaking News

Breaking news filtered in real-time to show only the most impactful headlines for US-listed public companies.

High Tide Closes Acquisition of a Majority Stake in Remexian Pharma GmbH

(NASDAQ:HITI) CALGARY, AB, Sept. 2, 2025 /PRNewswire/ - High Tide Inc. ("High Tide" or the "Company") (Nasdaq: HITI) (TSXV: HITI) (FSE: 2LYA), the high-impact, retail-forward enterprise built to de...

What impact will this deal have on High Tide's valuation and future growth prospects within the cannabis sector? How will the majority stake acquisition affect High Tide's cash flow and balance sheet liquidity? What are the expected financial synergies and cost savings from the acquisition of Remexian Pharma GmbH?
Symbol: HITI
Mergers
15 days ago
Read more prnewswire

HuhtamÀki Oyj announces final results of voluntary tender offer for its notes maturing in 2026 and 2027

(HUHT) HUHTAMÄKI OYJ STOCK EXCHANGE RELEASE 2.9.2025 AT 12:40 EEST

What is the expected impact of this tender on the equity market price and volatility of HUHT shares, and how might it influence investor positioning? How will the redemption of these notes affect HuhtamĂ€ki’s capital structure, liquidity, and credit profile in the short and medium term? What are the terms and pricing of the voluntary tender offer, and how do they compare to the current market levels of the 2026 and 2027 notes?
Symbol: HUHT
Finance
15 days ago
Read more globenewswire

US Food and Drug Administration (FDA) Approves Henlius and Organon’s BILDYOS¼ (denosumab-nxxp) and BILPREVDA¼ (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively

(NYSE:OGN) SHANGHAI & JERSEY CITY, N.J.--(BUSINESS WIRE)--FDA Approves Henlius and Organon’s BILDYOS¼ (denosumab-nxxp) and BILPREVDA¼ (denosumab-nxxp)

How does the entry of these biosimilars impact competition with Amgen’s Prolia and XGEVA and the broader bone‑health market? What revisions to revenue and market‑share estimates for denosumab biosimilars are anticipated following the approval? How will the FDA approval of BILDYOS¼ and BILPREVDA¼ affect Organon's near‑term stock price?
Symbol: OGN
Regulatory
15 days ago
Read more businesswire

Kodiak Gas Services Announces Changes to Its Board of Directors

(NYSE:KGS) THE WOODLANDS, Texas--(BUSINESS WIRE)--Kodiak Gas Services, Inc. (NYSE: KGS) (“Kodiak” or the “Company”) today announced the appointment of William (“Bill”) L. Bullock, Jr., former Execu...

What implications does this leadership addition have for Kodiak's upcoming earnings guidance and long-term growth prospects? Will the market view this board change as a positive catalyst for the stock, potentially driving the price higher? How will Bill Bullock's appointment influence Kodiak's strategic direction and financial performance?
Symbol: KGS
Board
15 days ago
Read more businesswire

NIO Inc. Reports Unaudited Second Quarter 2025 Financial Results

(NYSE:NIO) Quarterly Total Revenues Reached RMB19,008.7 million (US$2,653.5 million)i Quarterly Vehicle Deliveries were 72,056 units

Are there any indications of margin expansion or new product launches that could affect future profitability? What is the expected impact of 72,056 vehicle deliveries on NIO's market share and pricing power? How does the reported Q2 2025 revenue compare to analyst consensus forecasts?
Symbol: NIO
Earnings
15 days ago
Read more globenewswire